

Luxembourg, December 2024

Public

Environmental and Social Data Sheet¹

Overview

Project Name:	Resolve Biosciences (IEU TI)
Project Number:	2023-0552
Country:	Germany and Netherlands
Project Description:	The project supports the Promoter's activities related to research, development, regulatory requirements, and commercialisation, as well as IPs of its innovative High Resolution Pathology technology.

EIA required:	no
Invest EU sustainability proofing required	yes
Project included in Carbon Footprint Exercise ² :	no
(details for projects included are provided in section: "EIB Carbon Footprint Exercise")	

Environmental and Social Assessment

Environmental Assessment

The Promoter is an innovative company focused on the development and commercialization, including the creation of intellectual propriety, of a technology in the field of spatial biology, in particular in relation to high-resolution pathology.

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project activities are not listed under Annex I nor Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU, and as such these investment are not subject to EIA.

Climate Assessment

Research and development activities, such as those present in this Project, neither present significant negative nor positive impacts for climate aspects.

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, December 2024

The project is Paris aligned because i) it meets the low carbon criteria as set out in the Climate Bank Roadmap (Annex 2, Table B Industry i.e., RDI) and ii) is assessed as not materially at risk from physical climate hazards.

EIB Paris Alignment for Counterparties (PATH) Framework

The counterparty Resolve Biosciences BV is in scope but screened out of the PATH framework because it is not operating in a high emitting sector, and it is not considered as a highly vulnerable counterpart.

Social Assessment

The Project does not have significant negative social impacts, as the Promoter is expected to carry out its activities in compliance with applicable local labour and social standards.

For development and manufacturing activities, the Promoter collaborates and retains the services of subcontractors and relies on their official policies, processes, and qualifications, considering the high level of scrutiny and responsibility involved in such operations.

Other Environmental and Social Aspects

Considering the Promoter's small size and focus of the activities, currently it does not have any quality certification.

If successful, the project is expected to lead to important social benefits, considering the targeted applications of the technology and the level of potential unmet medical need in different therapeutic areas. Through the R&D activities and investments, the Promoter is also expected to sustain its current level of skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The Project's activities are not listed by EIA Directive 2011/92/EU amended by Directive 2014/52/EU. The research activities will be executed in existing and already authorised research facilities, expected to be in compliance with all applicable EU environmental legislation.

Considering the potential of the technology under development by the Promoter, the Project is expected to generate important social benefits, in particular in relation to the medical applications of such technology.

Sustainability proofing conclusion: the Project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environmental, climate and social information and based on the review of the likely significant environmental, climate and social risks and impacts and the mitigation measures and management systems in place, the Project is deemed to have low residual environmental, climate and social risks and impacts. No further sustainability proofing is therefore required.

Considering the above, the project is considered acceptable for Bank financing in environmental and social terms.